secwatch.observer — SEC 8-K summary
======================================

Issuer:     DiaMedica Therapeutics Inc. (DMAC)
CIK:        0001401040
Form:       8-K
Filed at:   2022-03-14T23:59:59+00:00
Accession:  0001437749-22-006162
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DiaMedica reports 2021 results: $45M cash, Phase 2/3 stroke trial underway
--------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities $45.1M as of Dec 31, 2021; runway into 2024.
- R&D expenses $8.8M for 2021 vs $8.2M prior year; net cash used in operations $12.3M.
- Pivotal Phase 2/3 ReMEDy2 trial for DM199 in acute ischemic stroke dosing patients; interim analysis planned after ~140 patients.
- Appointed Kirsten Gruis as CMO and Dom Cundari as CCO; last patient dosed in Phase 2 CKD REDUX trial.
- No revenue reported; net loss for 2021 not explicitly given but reflected in increased cash used.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401040/000143774922006162/0001437749-22-006162-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401040/000143774922006162/dmtp20220310_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-006162

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer